AbbVie Inc. (NYSE:ABBV – Get Free Report) shares rose 0.5% throughout buying and selling on Tuesday . The corporate traded as excessive as $198.97 and final traded at $198.43. Roughly 649,353 shares had been traded throughout buying and selling, a decline of 88% from the typical day by day quantity of 5,344,929 shares. The inventory had beforehand closed at $197.48.
Analysts Set New Value Targets
A variety of analysis companies have issued reviews on ABBV. William Blair raised AbbVie to a “strong-buy” ranking in a analysis report on Friday, August thirtieth. Piper Sandler Firms reaffirmed an “chubby” ranking and set a $190.00 value goal on shares of AbbVie in a analysis word on Wednesday, July third. Truist Monetary reiterated a “purchase” ranking and issued a $210.00 value goal (up beforehand from $195.00) on shares of AbbVie in a report on Friday, July twenty sixth. Cantor Fitzgerald restated an “chubby” ranking and set a $200.00 value goal on shares of AbbVie in a report on Monday, August fifth. Lastly, Wells Fargo & Firm boosted their value goal on AbbVie from $200.00 to $205.00 and gave the corporate an “chubby” ranking in a report on Friday, July twenty sixth. Two analysis analysts have rated the inventory with a maintain ranking, twelve have given a purchase ranking and two have assigned a powerful purchase ranking to the inventory. In response to MarketBeat, AbbVie presently has a median ranking of “Purchase” and a consensus value goal of $191.64.
View Our Newest Report on ABBV
AbbVie Inventory Down 0.3 %
The corporate’s 50 day shifting common value is $192.02 and its 200 day shifting common value is $176.34. The corporate has a fast ratio of 0.71, a present ratio of 0.81 and a debt-to-equity ratio of 8.51. The agency has a market capitalization of $347.73 billion, a price-to-earnings ratio of 58.88, a P/E/G ratio of two.65 and a beta of 0.64.
AbbVie (NYSE:ABBV – Get Free Report) final launched its quarterly earnings information on Thursday, July twenty fifth. The corporate reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.08. The corporate had income of $14.46 billion in the course of the quarter, in comparison with analysts’ expectations of $14.02 billion. AbbVie had a web margin of 9.71% and a return on fairness of 203.66%. The agency’s income for the quarter was up 4.3% on a year-over-year foundation. Throughout the identical quarter within the earlier yr, the corporate earned $2.91 earnings per share. As a gaggle, analysis analysts forecast that AbbVie Inc. will publish 10.86 earnings per share for the present fiscal yr.
AbbVie Declares Dividend
The corporate additionally just lately introduced a quarterly dividend, which will probably be paid on Friday, November fifteenth. Shareholders of report on Tuesday, October fifteenth will probably be issued a $1.55 dividend. The ex-dividend date is Tuesday, October fifteenth. This represents a $6.20 annualized dividend and a yield of three.15%. AbbVie’s payout ratio is 183.98%.
Insider Shopping for and Promoting at AbbVie
In associated information, Chairman Richard A. Gonzalez bought 66,500 shares of the corporate’s inventory in a transaction that occurred on Monday, August fifth. The shares had been bought at a median value of $186.52, for a complete transaction of $12,403,580.00. Following the sale, the chairman now straight owns 446,599 shares of the corporate’s inventory, valued at roughly $83,299,645.48. The sale was disclosed in a authorized submitting with the SEC, which is out there via this hyperlink. In different information, Chairman Richard A. Gonzalez bought 282,845 shares of the agency’s inventory in a transaction on Wednesday, July seventeenth. The shares had been bought at a median value of $175.00, for a complete worth of $49,497,875.00. Following the completion of the sale, the chairman now owns 513,099 shares within the firm, valued at roughly $89,792,325. The transaction was disclosed in a doc filed with the Securities & Alternate Fee, which might be accessed via this hyperlink. Additionally, Chairman Richard A. Gonzalez bought 66,500 shares of the agency’s inventory in a transaction dated Monday, August fifth. The shares had been bought at a median value of $186.52, for a complete transaction of $12,403,580.00. Following the completion of the sale, the chairman now owns 446,599 shares of the corporate’s inventory, valued at roughly $83,299,645.48. The disclosure for this sale might be discovered right here. 0.25% of the inventory is presently owned by firm insiders.
Hedge Funds Weigh In On AbbVie
Hedge funds and different institutional traders have just lately added to or diminished their stakes within the enterprise. Jones Monetary Firms Lllp raised its holdings in shares of AbbVie by 8.1% in the course of the fourth quarter. Jones Monetary Firms Lllp now owns 31,799 shares of the corporate’s inventory value $4,928,000 after buying a further 2,373 shares in the course of the interval. Belpointe Asset Administration LLC boosted its holdings in shares of AbbVie by 1.2% within the fourth quarter. Belpointe Asset Administration LLC now owns 34,550 shares of the corporate’s inventory value $5,354,000 after shopping for a further 403 shares in the course of the interval. Arbor Capital Administration Inc. ADV acquired a brand new place in shares of AbbVie within the fourth quarter value about $4,449,000. Royal London Asset Administration Ltd. lifted its place in shares of AbbVie by 7.3% within the fourth quarter. Royal London Asset Administration Ltd. now owns 1,374,846 shares of the corporate’s inventory value $213,060,000 after buying a further 93,443 shares within the final quarter. Lastly, Blueshift Asset Administration LLC bought a brand new stake in shares of AbbVie within the fourth quarter value roughly $775,000. Institutional traders and hedge funds personal 70.23% of the corporate’s inventory.
AbbVie Firm Profile
AbbVie Inc discovers, develops, manufactures, and sells prescription drugs worldwide. The corporate provides Humira, an injection for autoimmune and intestinal Behçet’s illnesses, and pyoderma gangrenosum; Skyrizi to deal with average to extreme plaque psoriasis, psoriatic illness, and Crohn’s illness; Rinvoq to deal with rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s illness; Imbruvica for the therapy of grownup sufferers with blood cancers; Epkinly to deal with lymphoma; Elahere to deal with most cancers; and Venclexta/Venclyxto to deal with blood cancers.
Beneficial Tales
Obtain Information & Rankings for AbbVie Day by day – Enter your e-mail tackle beneath to obtain a concise day by day abstract of the most recent information and analysts’ rankings for AbbVie and associated corporations with MarketBeat.com’s FREE day by day e-mail publication.
